TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00917865
Drug: anti [18F]FACBC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti\[18F\]FACBC (10mci) will be given intravenously over 1-2 minutes prior to obtaining PET-CT images At 4 minutes, 10 consecutive/4minutes images will be obtained of the pelvis to include the prostate.
Study: NCT00833365
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 10 mg/kg/dose for one dose, then repeated 24 hrs later at 5 mg/kg/dose and repeated 24 hrs later at 5 mg/kg/dose
Study: NCT00833365
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Initial dose of ibuprofen is 10 mg/kg and then repeated every 24 hours times two with doses of 5 mg/kg
Study: NCT01918644
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04005755
Drug: Maxigesic® IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: acetaminophen 1000 mg + ibuprofen 300 mg, 100 ml solution for infusion
Study: NCT00949845
Drug: Endotoxin
Normalized name: Endotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04256824
Drug: coated vicryl plus
Normalized name: VICRYL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coated Polyglactin 910 with Triclosan (coated vicryl plus)
Study: NCT04256824
Drug: Vicryl
Normalized name: VICRYL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coated Polyglactin 910 without Triclosan (vicryl)
Study: NCT03116516
Drug: Temisartan/Amlodipine+Rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive a single oral dose of temisartan/amlodipine+rosuvastatin administered in the morning.
Study: NCT03116516
Drug: YHP1604
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive a single oral dose of YHP1604 administered in the morning.
Study: NCT00381108
Drug: Placebo Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets, twice daily.
Study: NCT00866866
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tab PO BID
Study: NCT01227876
Drug: Ster
Normalized name: Oyster
DrugBank: Oyster (DB10550)
Approvals — FDA: no, EMA: no, PMDA: no
Description: prednisolone 1% ophthalmic suspension
Study: NCT03035422
Drug: Lymphocyte injection of prophylactic donor (PDLI)
Normalized name: lymphocyte immune globulin, anti-thymocyte globulin Injection [ATGAM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to the protocols of each center. In the absence of clinical indication against-disease (GVHD), phasing MMF between days D + 35 and D + 56, then phasing APF between D + 62 and D + 90~- PDLI: 3 injections from the D + 120 patients who discontinued immunosuppressive therapy for ≥ 1 month and having no active GVHD or history of acute GVHD grade\> II
Study: NCT00937508
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar pill without any active medication
Study: NCT00614679
Drug: catheter lock solution consisting of N-acetylcystein, tigecycline and heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcystein 80 mg/ml, tigecycline 1 mg/ml, and heparin 2000 units/ml. This will be a 5 ml catheter lock solution
Study: NCT01347073
Drug: HPN-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPN-100 is a pro-drug of PAA that combines with glutamine to provide an alternative vehicle for waste nitrogen elimination. It is a liquid with minimal taste and odor. Approximately three teaspoons of HPN-100 (\~17.4 mL) delivers an equivalent amount as PBA that 40 tablets of NaPBA.
Study: NCT00626340
Drug: MDD diagnosis with both Estrogen and Fluoxetine treatment
Normalized name: testosterone and estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with estrogen and fluoxetine combined.
Study: NCT01872026
Drug: ASP7991
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00626340
Drug: No depression and estrogen treatment
Normalized name: testosterone and estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control participants with no MDD diagnosis received estrogen only for the treatment of physical symptoms of menopause.
Study: NCT00638534
Drug: Telithromycin (HMR3647)
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03634085
Drug: BDM-2 in Bottle (50 mg - 3600 mg); oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDM-2 in bottle will be reconstituted with a 100 mL vehicle (0.2% Sodium Dodecyl Sulfate and water) to achieve a suspension for oral administration.
Study: NCT01889875
Drug: ALK Grazax 75,000 SQ-T Phleum pratense
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02072213
Drug: Omix Ocas
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4mg once a day
Study: NCT00945282
Drug: GSK2248761
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2248761 30 mg capsule once a day for 7 days. GSK2248761 is an investigational (not approved by the FDA) HIV drug in the class of non-nucleoside reuptake inhibitor class.
Study: NCT00945282
Drug: HAART
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly Active Antiretroviral therapy of the doctor's choice.
Study: NCT00945282
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a capsule with no drug in it.
Study: NCT00945282
Drug: GSK2248761
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2248761 10 mg -20 mg or 40 mg - 90 mg once a day for 7 days. GSK2248761 is an investigational (not approved by the FDA) HIV drug in the class of non-nucleoside reuptake inhibitor class.
Study: NCT02314325
Drug: ADVATE [Antihemophilic Factor (Recombinant)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Arm 1 prior patients will be dosed as per body weight 20-40 IU/kg 5-7 infusions per fortnight
Study: NCT02314325
Drug: ADVATE [Antihemophilic Factor (Recombinant)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Arm 2 patients who have completed arm 1 will cross over onto an individualised PK tailored alternate day dosing regimen
Study: NCT03393117
Drug: Oral Narcotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral narcotics will be offered when the patient's diet is advanced as tolerated, typically post-operative day 1.
Study: NCT00152893
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04354376
Drug: Loop diuretics, thiazides, dihydropyridines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loop diuretics, thiazides, or dihydropyridines dispensing claim is used as the reference
Study: NCT00890825
Drug: AZD6244
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsules, 75mg twice daily
Study: NCT00890825
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02707913
Drug: Norvasc Tablet 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norvasc Tablet 10mg will be used as a comparator drug for the BE study
Study: NCT01370707
Drug: CJ-30001/CJ-30002
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6/1500mg\~0.9/1500mg/day, 24weeks
Study: NCT01879683
Drug: LiRIS® 400 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: LiRIS® 400 mg is a drug-device combination product which is placed in the bladder during cystoscopy, remains in the bladder for up to 14 days gradually releasing lidocaine, and removed from the bladder via cystoscopy.
Study: NCT00777816
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of placebo on Day 0, administered either as an intravenous (IV) infusion or as a subcutaneous (SC) injection.
Study: NCT04507945
Drug: Nutritional Therapy, Metabolic Disorder, Regular
Normalized name: nutritional therapy, metabolic disorder, regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to the result reported by Byrne, Wilmore, etc. in 1992 \~ 1995, the use of growth hormone, glutamine, modified diet and other measures proposed intestinal rehabilitation treatment. Then, check the patient's quality of life survey, nutritional status, inflammation indicators and other changes every three months, and use metabolomics and microbiomic tools to detect changes in the patient's nutritional metabolism, intestinal microecology, etc., and adjust the patient's nutritional treatment and microecological treatment based on the results Program.
Study: NCT00917241
Drug: MMI
Normalized name: Rommix
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMI treatment with titration regimen for 18 months, initial dosage was 20 mg/d.
Study: NCT00076414
Drug: Acetylcholine
Normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00758433
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch q.d. 24 hours for 7 days
Study: NCT00741052
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 gm Azithromycin single dose
Study: NCT01919229
Drug: LEE011 (ribociclib)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib was supplied in 200 mg hard gelatin capsules for oral use.
Study: NCT01353963
Drug: desvenlafaxine succinate
Normalized name: Desvenlafaxine Succinate
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg tablet once daily
Study: NCT00507169
Drug: SVT-40776
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03616470
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline, 0.9% Sodium Chloride
Study: NCT01204749
Drug: AMG 386 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly Intravenous (IV) placebo 15 mg/kg
Study: NCT01929590
Drug: PEG-3350 group 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: split-dose (PEG-3350; 2 L the day before 17:00-19:00 h and 2 L same day of the procedure 06:00-08:00 am)
Study: NCT01929590
Drug: PEG-3350 group 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-3350; PEG-4 L the day previous of the study, starting at 17:00 and finishing at 21:00 h
Study: NCT01929590
Drug: PEG-3350 group 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: low-volume 2 L PEG-solution (same day of the procedure 06:00-08:00 am)
Study: NCT02109640
Drug: Targinact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative analgesia
Study: NCT00297674
Drug: Intravenous Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02808585
Drug: PB1046 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four weekly subcutaneous injections of PB1046.
Study: NCT02808585
Drug: Placebo Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four weekly subcutaneous injections of placebo.
Study: NCT03658967
Drug: Lymfactin® (1x10E11 vp)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymfactin® will be administered as a single dose via perinodal injection in a volume of 2 mL.
Study: NCT03658967
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as a single dose via perinodal injection in a volume of 2 mL.
Study: NCT00113906
Drug: melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03703778
Drug: Androgen deprivation therapy - GnRH agonist
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) is a kind of hormone therapy for prostate cancer. The goal is to reduce levels of male hormones, called androgens, in the body, or to stop them from affecting prostate cancer cells. It can be surgical, i.e. bilateral orchidectomy, or medical, i.e. GnRH agonist or GnRH antagonist.
Study: NCT03703778
Drug: Androgen deprivation therapy - GnRH antagonist
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) is a kind of hormone therapy for prostate cancer. The goal is to reduce levels of male hormones, called androgens, in the body, or to stop them from affecting prostate cancer cells. It can be surgical, i.e. bilateral orchidectomy, or medical, i.e. GnRH agonist or GnRH antagonist.
Study: NCT02519023
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine.
Study: NCT02519023
Drug: acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: all individuals will receive scheduled acetaminophen (1 gram every 6 hours),
Study: NCT02519023
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: all individuals will receive scheduled ibuprofen (800 mg every 8 hours)
Study: NCT01401985
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules
Study: NCT00617201
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral dosing - matched placebo
Study: NCT00626275
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00626275
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00495729
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive matching placebo tablets to SB-649868 orally 1 hour prior to simvastatin administration.
Study: NCT00495729
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive Simvastatin 10 mg tablets orally.
Study: NCT03599453
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by mouth
Study: NCT04281108
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally disintegrating tablet.
Study: NCT00744926
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sc, once weekly
Study: NCT02910635
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01803555
Drug: SYMBICORT® TURBOHALER®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symbicort Turbohaler will be administered per dose and schedule specified in the arm.
Study: NCT01803555
Drug: SYMBICORT placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYMBICORT placebo multi-dose dry powder inhaler (DPI) identical in appearance to SYMBICORT TURBOHALER will be administered per dose and schedule specified in the arm.
Study: NCT01803555
Drug: SPIROMAX Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPIROMAX Placebo multi-dose dry powder inhaler (DPI) identical in appearance to BF SPIROMAX will be administered per dose and schedule specified in the arm.
Study: NCT02302586
Drug: Patient Controlled Analgesia (IV PCA)
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV morphine patient controlled analgesia (PCA) is being used in the postoperative period for 48 hours. Basal infusion: 0.3 mg/kg/h, Bolus: 1 mg, Lock-out time: 20 min, 4-h limit: 10-12,5 mg
Study: NCT02576223
Drug: Isotonic Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline injected perineural at the suprascapular nerve.
Study: NCT02576223
Drug: PCA-pump
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA (Patient controlled analgesia) pump with the following settings:~Age \> 70 years or weight \< 60 kg: bolus dose 2,5 mg i.v. morphine, 15 minutes lockout Age \< 70 years and weight \> 60 kg: bolus dose 5 mg i.v. morphine, 15 minutes lockout Lockout time 15 minutes.
Study: NCT01721161
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses)
Study: NCT00861510
Drug: ON01910 Na
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00174434
Drug: SU011248
Approvals — FDA: no, EMA: no, PMDA: no
Description: SU011248 provided as capsules. The starting dose is 25 mg orally, daily in a continuous regimen beginning on day 2. Dose rest for 1 week is allowed. Dose escalation to 37.5 mg po OD is allowed within the constraints of acceptable toxicity parameters. Dosing will continue for 1 year or until disease progression or unacceptable toxicity, whichever comes first.
Study: NCT01420549
Drug: Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tables containing: Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.
Study: NCT00376519
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 60 mg/kg/day will be administered as a 2 hour intravenous infusion with a high volume fluid flush and mesna (MT(S)9006) on day -8 and -7 one hour after fludarabine infusion.
Study: NCT03775798
Drug: Direct antiviral agents for hepatitis C
Normalized name: hepatitis C virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting antivirals for hepatitis C
Study: NCT02252328
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 80mg once daily
Study: NCT02252328
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets once daily
Study: NCT02940561
Drug: Methotrexate - Amneal
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate Tablets, USP contain an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate, USP and are round, biconvex, yellow tablets, scored in half on one side, engraved with A above the score and 1 below
Study: NCT02940561
Drug: Methotrexate - DAVA
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate Tablets, USP contain an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate and are round, convex, yellow tablets, scored in half on one side, engraved with M above the score, and 1 below
Study: NCT00774852
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg intravenous infusion every 2 weeks for 12 weeks
Study: NCT00774852
Drug: azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 mg/kg/day orally from weeks 12-28; continue until week 52 if only partial response observed at week 24
Study: NCT00774852
Drug: azathioprine placebo
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral capsule, daily from weeks 28 to 52, only if complete response observed at week 24
Study: NCT01251354
Drug: BN83495
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of 40 mg, oral, daily until progression or death or unacceptable toxicity develops
Study: NCT00832091
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: There were 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There was one concentration of placebo gel for topical administration to the placebo group. The concentration was 0.0% weight/weight (w/w) thymosin beta 4 gel applied once daily for up to 84 days
Study: NCT00148759
Drug: LPV/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPV/r 800/200 mg once daily
Study: NCT02753946
Drug: ZTI-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6g ZTI-01 intravenous infusion TID q8 hours
Study: NCT04001712
Drug: Caffeine Citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: caffeine citrate is given early to preterm neonates in need of respiratory support
Study: NCT03697876
Drug: PRO-165
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRO-165 Chondroitin sulfate 0.18% / sodium hyaluronate 0.2%, ophthalmic gel. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.
Study: NCT03697876
Drug: Artelac
Normalized name: Artelac Nighttime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artelac® Nightime Gel. 0.2% Carbomer, ophthalmic gel. Made in Germany by: Dr. Gerhard Mann Chem Pharm. Imported and marketed by: Bausch \& Lomb México, S.A. de C.V.
Study: NCT02741245
Drug: Rosuvastatin 2.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02741245
Drug: Placebo for Rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02784795
Drug: LY3039478
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02784795
Drug: LY3023414
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03980730
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsule administered orally, once daily
Study: NCT01949974
Drug: Standard Palliative Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Palliative Chemotherapy, depending on type cancer.
Study: NCT00605228
Drug: COLOPEG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4L Drug
Study: NCT00004127
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004127
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01365286
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo b.i.d. for 5 days and Ivabradine 7,5 mg b.i.d. for 5 days (Placebo-Ivabradine)
Study: NCT02407223
Drug: Group 1: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo SC at Weeks 0, 4, 16, and 20. At Week 24, all participants (except those who early escaped) will crossover to receive ustekinumab 45 or 90 mg SC at Weeks 24 and 28 followed by every 12 weeks up to Week 52. At Week 16, participants in placebo group with \< 10% improvement from baseline in both total back pain and morning stiffness measures at Week 12 and 16 will enter early escape to receive ustekinumab 45 mg or 90 mg at Weeks 16, 20, and 28 followed by every 12 weeks up to Week 52. At Week 52, participants who achieved inactive disease by ASDAS (ESR) \<1.3 at both Week 40 and 52 will be re-randomized to receive placebo or ustekinumab every 12 weeks up to Week 88. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) \<1.3 at Week 40 or 52 will continue with ustekinumab every 12 weeks up to Week 88.
Study: NCT03365622
Drug: acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Intravenous doses will consist of a single 1,000mg/100 ml IV dose with contents of commercial vials transferred to an empty sterile IV bag.
Study: NCT03365622
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg acetaminophen tablet ,2 capsules oral every six hours for 24 hours
Study: NCT03365622
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Intravenous doses will consist of 100ml of normal saline transferred to an empty sterile IV bag.